Lundbeck leaves Trintellix to partner Takeda in the US, opting for royalties as it focuses efforts on Rexulti

The end of an era is nearing for Lundbeck. After a 17-year collaboration with Takeda on depression drug Trintellix, the Danish drugmaker is passing over its U.S. rights to its partner.

Effective January 1 of next year, Lundbeck will collect only royalties on the med in the U.S. market after switching from their current arrangement, which features shared promotion efforts, costs and revenues as well as royalties.